stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) EBITDA
BridgeBio Pharma, Inc.'s EBITDA for fiscal 2025 was −$512.0M, compared with −$579.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$352.4M. Over the past ten years it has ranged from −$592.0M (fiscal 2023) to −$43.9M (fiscal 2017); the current reading is higher than 44% of that period. BridgeBio Pharma, Inc. ranks 559th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$512.0M | — |
| FY2024 | −$579.4M | — |
| FY2023 | −$592.0M | — |
| FY2022 | −$505.4M | — |
| FY2021 | −$570.8M | — |
| FY2020 | −$473.0M | — |
| FY2019 | −$265.4M | — |
| FY2018 | −$183.7M | — |
| FY2017 | −$43.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$8.6M | — |
| Jun 2026 | −$104.1M | — |
| Mar 2026 | −$103.0M | — |
| Dec 2025 | −$136.7M | — |
| 28 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.1B |
| EXEL Exelixis, Inc. compare | $1.0B |
| HALO Halozyme Therapeutics, Inc. compare | $719.2M |
| BMRN BioMarin Pharmaceutical Inc. compare | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. | −$352.4M |
| KYMR Kymera Therapeutics, Inc. compare | −$405.5M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement